ArticleProceedings of the National Academy of Sciences of the United States of America2012
Analysis of sirtuin 1 expression reveals a molecular explanation of IL-2-mediated reversal of T-cell tolerance.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- Effects of resveratrol on the anthropometric indices and inflammatory markers: an umbrella meta-analysis.European journal of nutrition · 2024Pooled it
- Anti-inflammatory phytochemicals from medicinal herbs based on senoinflammation schema for healthy aging.Archives of pharmacal research · 2026Review
- Optimizing DCD donor liver function with resveratrol during machine perfusion.Scientific reports · 2025Article
- Epigenetics and Mitochondrial Biogenesis: The Role of Sirtuins in HIV Neuropathogenesis.Molecular neurobiology · 2025Article
- Promising potential effects of resveratrol on oral and dental health maintenance: a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- A comprehensive review on the neuroprotective potential of resveratrol in ischemic stroke.Heliyon · 2024Review
- Patent Mining on the Use of Antioxidant Phytochemicals in the Technological Development for the Prevention and Treatment of Periodontitis.Antioxidants (Basel, Switzerland) · 2024Review
- SIRT1 inactivation switches reactive astrocytes to an antiinflammatory phenotype in CNS autoimmunity.The Journal of clinical investigation · 2022Article
- Nicotinamide adenine dinucleotide metabolism in the immune response, autoimmunity and inflammageing.British journal of pharmacology · 2022Review
- Sirtuins are crucial regulators of T cell metabolism and functions.Experimental & molecular medicine · 2022Review
- Review
- Review
- Immune Aging and Immunotherapy in Cancer.International journal of molecular sciences · 2021Review
- Anti-Inflammatory Action and Mechanisms of Resveratrol.Molecules (Basel, Switzerland) · 2021Review
- Intermittent Hypoxic Preconditioning: A Potential New Powerful Strategy for COVID-19 Rehabilitation.Frontiers in pharmacology · 2021Review
- Metabolic signaling in T cells.Cell research · 2020Review
- Decreased SIRT1 expression in the peripheral blood of patients with Graves' disease.The Journal of endocrinology · 2020Article
- CD38: T Cell Immuno-Metabolic Modulator.Cells · 2020Review
- The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment.Cells · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The type III histone deacetylase sirtuin 1 (Sirt1) is a suppressor of both innate and adoptive immune responses. We have recently found that Sirt1 expression is highly induced in anergic T cells. However, the transcriptional program to regulate Sirt1 expression in T cells remains uncharacterized. Here we report that the early responsive genes 2 and 3, which can be up-regulated by T-cell receptor-mediated activation of nuclear factor of activated T-cell transcription factors and are involved in peripheral T-cell tolerance, bind to the sirt1 promoter to transcript sirt1 mRNA. In addition, the forkhead transcription factor, FoxO3a, interacts with early responsive genes 2/3 on the sirt1 promoter to synergistically regulate Sirt1 expression. Interestingly, IL-2, a cytokine that can reverse T-cell anergy, suppresses sirt1 transcription by sequestering FoxO3a to the cytoplasm through activating the PI3K-AKT pathway. Expression of the constitutively active form of FoxO3a blocks IL-2-mediated reversal of T-cell tolerance by retaining sirt1 expression. Our findings here provide a molecular explanation of IL-2-mediated reversion of T-cell anergy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.